{"title":"Correction to “Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression”","authors":"","doi":"10.1111/hepr.14167","DOIUrl":null,"url":null,"abstract":"<p>Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i>. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.</p><p>In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.</p><p>This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”</p><p>We apologize for this error.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 5","pages":"781"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.14167","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644.
In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect.
This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…”
期刊介绍:
Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.